Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study
Gb. Pajno et al., Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study, ALLERGY, 55(9), 2000, pp. 842-849
Background: Immunotherapy through local routes is thought to be a valuable
therapeutic option for respiratory allergy. We investigated the clinical ef
ficacy and immunologic effects of sublingual immunotherapy (SLIT) in asthma
tic children with mite-induced respiratory allergy.
Methods: Twenty-four patients (age range 8-15 years), suffering from mild t
o moderate asthma, with single sensitization to mite allergen, were enrolle
d. After a 1-year observation phase, patients were randomly allocated to on
e of two groups, and were given SLIT (sublingual-spit) as drops for 2 years
according to a double-blind, placebo-controlled (DBPC) design. Symptoms/me
dication scores (diary card), visual analog scale, and immunologic paramete
rs (house-dust-mite [HDM]-specific IgE, and total HDM-specific IgG and IgG4
) were determined during the observation phase and during the DBPC treatmen
t period.
Results: Twenty-one patients completed the study. At the beginning of the t
reatment, no difference in environmental allergenic pressure could be shown
between the groups. After 2 years of therapy, there was a significant decr
ease ill asthmatic symptoms (P = 0.0001) and medication use (P = 0.0001) in
the active group compared to the placebo group. The visual analog score on
overall asthma symptoms improved in the SLIT group (P = 0.0001), but not i
n the placebo group. Nevertheless, the immunologic results did not show sig
nificant differences in HDM-specific IgE and total HDM-specific IgG or IgG4
between the active and placebo groups (P = NS). No relevant side-effects w
ere recorded throughout the study.
Conclusions: Our results suggest that treatment for 2 years with SLIT is cl
inically safe and effective in significantly decreasing respiratory symptom
s in children with mild to moderate asthma sensitized to HDM. On the other
hand, the lack of changes of the immunologic parameters calls for further i
nvestigations with special reference to kinetics and mechanism(s) of action
of this mode of treatment.